Design Therapeutics, Inc. (NASDAQ:DSGN - Get Free Report) was up 1.3% during trading on Monday . The company traded as high as $5.60 and last traded at $5.40. Approximately 154,551 shares traded hands during trading, an increase of 33% from the average daily volume of 116,630 shares. The stock had previously closed at $5.33.
Design Therapeutics Trading Up 1.3%
The firm has a market cap of $307.53 million, a PE ratio of -4.82 and a beta of 1.58. The business's 50-day simple moving average is $4.07 and its 200 day simple moving average is $4.08.
Design Therapeutics (NASDAQ:DSGN - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.02). Analysts expect that Design Therapeutics, Inc. will post -0.91 earnings per share for the current year.
Institutional Trading of Design Therapeutics
A number of institutional investors have recently modified their holdings of DSGN. Los Angeles Capital Management LLC acquired a new stake in Design Therapeutics in the 2nd quarter worth approximately $43,000. Invesco Ltd. lifted its stake in Design Therapeutics by 26.8% during the 2nd quarter. Invesco Ltd. now owns 14,364 shares of the company's stock valued at $48,000 after acquiring an additional 3,033 shares during the period. Velan Capital Investment Management LP acquired a new stake in Design Therapeutics during the 1st quarter valued at approximately $54,000. Jane Street Group LLC acquired a new stake in Design Therapeutics during the 1st quarter valued at approximately $70,000. Finally, ProShare Advisors LLC acquired a new stake in Design Therapeutics during the 4th quarter valued at approximately $71,000. 56.64% of the stock is currently owned by institutional investors.
Design Therapeutics Company Profile
(
Get Free Report)
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Design Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.
While Design Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access